Conjugated estrogens/medroxyprogesterone - Pfizer

Drug Profile

Conjugated estrogens/medroxyprogesterone - Pfizer

Alternative Names: Methylprogesteron/conjugated estrogens; Premarin®/MPA; Prempak-C; Premphase; Premplus; Prempro

Latest Information Update: 14 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Hormonal replacements; Osteoporosis therapies
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 01 Jul 2003 Launched for Menopausal syndrome in Canada (PO)
  • 01 Jul 2003 Launched for Menopausal syndrome in Ireland (PO)
  • 01 Jul 2003 Launched for Menopausal syndrome in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top